<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04895293</url>
  </required_header>
  <id_info>
    <org_study_id>RKM-011</org_study_id>
    <nct_id>NCT04895293</nct_id>
  </id_info>
  <brief_title>RBM-007 in Treatment naïve Exudative Age-related Macular Degeneration</brief_title>
  <acronym>TEMPURA</acronym>
  <official_title>Evaluation of RBM-007 in Subjects With Treatment naïve Exudative Age-related Macular Degeneration (AMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maturi, Raj K., M.D., P.C.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maturi, Raj K., M.D., P.C.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single-center, open label, 4-month study, designed to evaluate the safety and&#xD;
      treatment efficacy of RBM-007 in patients with intraretinal or subretinal edema due to&#xD;
      previously untreated neovascular AMD. Up to 5 subjects will be randomized to receive study&#xD;
      medication. Study treatment will be administered by intravitreal injections.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2021</start_date>
  <completion_date type="Anticipated">July 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All subjects receive the study treatment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Macular edema</measure>
    <time_frame>3 months</time_frame>
    <description>Central subfield thickness on optical coherence tomography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>3 Months</time_frame>
    <description>Change from Baseline in Best Corrected Visual Acuity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>RBM-007 Injectable Solution - 0.2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravitreal injection in study eye</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RBM-007 Injectable Solution</intervention_name>
    <description>Sterile solution</description>
    <arm_group_label>RBM-007 Injectable Solution - 0.2 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        • General Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients, 50 years of age or older at baseline&#xD;
&#xD;
          2. Patient has completed/signed an informed consent prior to any study-related procedures&#xD;
             and is able to follow study instructions and likely to complete all required visits.&#xD;
&#xD;
             • Ocular Inclusion Criteria:&#xD;
&#xD;
          3. Best Corrected Visual Acuity (BCVA) 5 - 73 ETDRS letters (20/800-20/40 Snellen&#xD;
             equivalent), inclusive, in study eye&#xD;
&#xD;
          4. Presence of choroidal neovascularization secondary to AMD&#xD;
&#xD;
          5. Clear ocular media and adequate pupil dilation to permit good quality photographic&#xD;
             imaging.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        • General Exclusion Criteria:&#xD;
&#xD;
          1. Females who are pregnant, nursing, planning a pregnancy or who are of childbearing&#xD;
             potential not using a reliable method of contraception.&#xD;
&#xD;
          2. History or current evidence of hypersensitivity to any components of the study&#xD;
             medication or fluorescein, as assessed by the investigator.&#xD;
&#xD;
          3. Participation in any investigational drug or device study within 30 days prior to&#xD;
             baseline&#xD;
&#xD;
          4. History or current evidence of a medical condition that may, in the opinion of the&#xD;
             investigator, preclude the safe administration of study medication or affect the&#xD;
             results of the study.&#xD;
&#xD;
             • Ocular Exclusion Criteria:&#xD;
&#xD;
          5. Active ocular or periocular infections, malignancy&#xD;
&#xD;
          6. Aphakia&#xD;
&#xD;
          7. History of pars plana vitrectomy in the study eye&#xD;
&#xD;
          8. History of major ophthalmic surgery in the past 3 months in the study eye, or minor&#xD;
             surgery in the past 30 days&#xD;
&#xD;
          9. History of significant ocular disease other than exudative AMD that may confound&#xD;
             results&#xD;
&#xD;
         10. Uncontrolled glaucoma (defined as intraocular pressure &gt;21mm Hg despite treatment with&#xD;
             ocular hypotensive medications at baseline).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raj K. Maturi, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Midwest Eye Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vinaya Mahesh</last_name>
    <phone>317-805-2198</phone>
    <email>vinayam@midwesteye.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Midwest Eye Institute</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vinaya M Mahesh</last_name>
      <phone>317-805-2198</phone>
      <email>vinayam@midwesteye.com</email>
    </contact>
    <contact_backup>
      <last_name>Lorraine White</last_name>
      <phone>317-817-1414</phone>
      <email>Lorrainew@midwesteye.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 17, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2021</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

